Literature DB >> 30039225

Preoperative prediction of deep myometrial invasion and tumor grade for stage I endometrioid adenocarcinoma: a simple method of measurement on DWI.

Bin Yan1, Xiufen Liang2, Tingting Zhao3, Chen Niu3, Caixia Ding4, Wenjun Liu5.   

Abstract

OBJECTIVES: To explore the utility of the tumor area ratio (TAR) for predicting deep myometrial invasion and tumor grade in stage I endometrioid adenocarcinoma (EEA).
METHODS: We retrospectively evaluated 86 patients with International Federation of Gynecology and Obstetrics (FIGO) stage I EEA. All patients underwent unenhanced contrast MRI and diffusion-weighted imaging (DWI) procedures. The volume and maximum area of the tumor and uterus were obtained, and the tumor volume ratio (TVR) and TAR were calculated. The Kruskal-Wallis test and Mann-Whitney U test were used to compare the differences in indexes (TVR and TAR) between the different tumor grades and between superficial and deep myometrial invasion.
RESULTS: The TVR and TAR values for deep myometrial invasion and high-grade EEA tumors were significantly higher than the values for superficial myometrial invasion and low-grade tumors (all p = 0.000). According to the receiver-operating characteristic (ROC) curve, the area under the curve (AUC) was significantly higher for TAR than for TVR for tumors with deep myometrial invasion (0.936 vs. 0.844, p = 0.045). However, no significant differences in the AUCs for TVR and TAR were observed between high- and low-grade tumors (0.865 vs. 0.863, p = 0.956). A TAR ≥ 34.6% predicted deep myometrial invasion in EEA with a sensitivity, specificity, and accuracy of 85.0%, 84.8%, and 86.0%, respectively. A TAR ≥ 38.9% predicted high-grade tumors with a sensitivity, specificity, and accuracy of 83.3%, 81.1%, and 82.6%, respectively.
CONCLUSION: TAR is useful for predicting deep myometrial invasion and high-grade stage I EEA KEY POINTS: • TAR is useful for predicting risk factors for EEA. • TAR is easy to obtain and has high accuracy. • TAR has excellent interobserver repeatability agreement (ICC range 95.1-99.6%).

Entities:  

Keywords:  Cell differentiation; Diffusion; Endometrioid adenocarcinoma; Magnetic resonance imaging; Neoplasm staging

Mesh:

Year:  2018        PMID: 30039225     DOI: 10.1007/s00330-018-5653-2

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  26 in total

1.  Measurement of the minimum apparent diffusion coefficient (ADCmin) of the primary tumor and CA125 are predictive of disease recurrence for patients with endometrial cancer.

Authors:  Keiichiro Nakamura; Noriaki Imafuku; Takeshi Nishida; Ieyasu Niwa; Ikuo Joja; Atsushi Hongo; Junichi Kodama; Yuji Hiramatsu
Journal:  Gynecol Oncol       Date:  2011-10-18       Impact factor: 5.482

2.  Staging of endometrial cancer with MRI: guidelines of the European Society of Urogenital Imaging.

Authors:  K Kinkel; R Forstner; F M Danza; L Oleaga; T M Cunha; A Bergman; J O Barentsz; C Balleyguier; B Brkljacic; J A Spencer
Journal:  Eur Radiol       Date:  2009-02-05       Impact factor: 5.315

3.  Myometrial invasion in endometrial cancer: diagnostic accuracy of diffusion-weighted 3.0-T MR imaging--initial experience.

Authors:  Gigin Lin; Koon-Kwan Ng; Chee-Jen Chang; Jiun-Jie Wang; Kung-Chu Ho; Tzu-Chen Yen; Tzu-I Wu; Chun-Chieh Wang; Yu-Ruei Chen; Yu-Ting Huang; Shu-Hang Ng; Shih-Ming Jung; Ting-Chang Chang; Chyong-Huey Lai
Journal:  Radiology       Date:  2009-03       Impact factor: 11.105

Review 4.  Endometrial cancer.

Authors:  Frederic Amant; Philippe Moerman; Patrick Neven; Dirk Timmerman; Erik Van Limbergen; Ignace Vergote
Journal:  Lancet       Date:  2005 Aug 6-12       Impact factor: 79.321

5.  Endometrial cancer: correlation of apparent diffusion coefficient with tumor grade, depth of myometrial invasion, and presence of lymph node metastases.

Authors:  Gilda Rechichi; Stefania Galimberti; Mauro Signorelli; Cammillo Talei Franzesi; Patrizia Perego; Maria Grazia Valsecchi; Sandro Sironi
Journal:  AJR Am J Roentgenol       Date:  2011-07       Impact factor: 3.959

6.  Clinical significance of tumor volume in endometrial cancer: a Japan-Korea cooperative study.

Authors:  Yukiharu Todo; Hyuck-Jae Choi; Sokbom Kang; Jae-Weon Kim; Joo-Hyun Nam; Hidemichi Watari; Akiko Tamakoshi; Noriaki Sakuragi
Journal:  Gynecol Oncol       Date:  2013-08-14       Impact factor: 5.482

7.  Diffusion-weighted imaging in the assessment of tumour grade in endometrial cancer.

Authors:  N Bharwani; M E Miquel; A Sahdev; P Narayanan; G Malietzis; R H Reznek; A G Rockall
Journal:  Br J Radiol       Date:  2011-09-06       Impact factor: 3.039

8.  Endometrial cancer: utility of diffusion-weighted magnetic resonance imaging with background body signal suppression at 3T.

Authors:  Jung Min Seo; Chan Kyo Kim; Dongil Choi; Byung Kwan Park
Journal:  J Magn Reson Imaging       Date:  2012-11-13       Impact factor: 4.813

9.  Diffusion-weighted MR imaging of uterine endometrial cancer.

Authors:  Ken Tamai; Takashi Koyama; Tsuneo Saga; Shigeaki Umeoka; Yoshiki Mikami; Shingo Fujii; Kaori Togashi
Journal:  J Magn Reson Imaging       Date:  2007-09       Impact factor: 4.813

10.  Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.

Authors:  Pierluigi Benedetti Panici; Stefano Basile; Francesco Maneschi; Andrea Alberto Lissoni; Mauro Signorelli; Giovanni Scambia; Roberto Angioli; Saverio Tateo; Giorgia Mangili; Dionyssios Katsaros; Gaetano Garozzo; Elio Campagnutta; Nicoletta Donadello; Stefano Greggi; Mauro Melpignano; Francesco Raspagliesi; Nicola Ragni; Gennaro Cormio; Roberto Grassi; Massimo Franchi; Diana Giannarelli; Roldano Fossati; Valter Torri; Mariangela Amoroso; Clara Crocè; Costantino Mangioni
Journal:  J Natl Cancer Inst       Date:  2008-11-25       Impact factor: 13.506

View more
  1 in total

1.  Machine Learning-Based Gray-Level Co-Occurrence Matrix (GLCM) Models for Predicting the Depth of Myometrial Invasion in Patients with Stage I Endometrial Cancer.

Authors:  Xiaoyuan Qian; Du He; Li Qin; Lin Lai; Hongli Wang; Yukun Zhang
Journal:  Cancer Manag Res       Date:  2022-06-30       Impact factor: 3.602

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.